Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial)

Author(s):: Willemze, R.; Muus, P.; Halkes, S.J.M.; Meloni, G.; Suciu, S.; Meert, L.; Flament, J.; Karrasch, M.; Vignetti, M.; Amadori, S.; Witte, T.M. de; Marie, J.P.

Published: 2011
Publication type: Article / Letter to editor

Date issued: 2011-11-18
Language: English
Is part of: Blood (2011), Vol. 118, no. 21, p. 1120-1121
hdl: 1887/97764